Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What are the unmet needs in the treatment of HR-positive, HER2-negative early breast cancer and what factors influence the likelihood of recurrence? (0:12)
- Could you tell us a little about the aims, design and findings of the MonarchE clinical trial? (1:15)
- What is the clinical significance of these findings and how are they likely to impact on future clinical practice? (2:45)
- What other agents that could be effectively combined with CDK4/6 inhibitors, beyond endocrine therapy? (4:09)
- What will be the next steps in the clinical development of abemaciclib in breast cancer therapy? (6:02)
Speaker Disclosures: Stephen Johnston has provided consultancy for Novartis, Pfizer, Eli Lilly, Puma Biotechnology; has received speaker honoraria from Eisai, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche; and has received research funding for his institution from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. The MonarchE trial was sponsored by Eli Lilly and Company.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Breast Cancer
Lynsey Drewett, AACR 2022: Olaparib in Combination With Neoadjuvant Platinum-based Chemotherapy – the PARTNER Study
It was a pleasure to speak with Dr Lynsey Drewett (University of Cambridge, Cambridge, UK) around the PARTNER study, investigating the efficacy and safety of the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer. The abstract ‘PARTNER: Randomised, phase II/III trial to evaluate the safety and […]
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!